---
title: "Mabwell Plans Up to RMB 1 Billion Targeted Debt Issue to Reshape Capital Structure"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285408743.md"
description: "Mabwell (Shanghai) Bioscience Co., Ltd. plans to issue targeted debt financing instruments of up to RMB 1 billion to optimize its capital structure. The bonds, with terms of up to three years, will be issued in the interbank bond market to institutional investors. Proceeds will be used for repaying liabilities, funding project construction, and replenishing working capital. The board has approved the proposal, pending shareholder approval and regulatory clearance. Mabwell focuses on developing innovative biologic therapies and is listed in Hong Kong."
datetime: "2026-05-06T14:39:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285408743.md)
  - [en](https://longbridge.com/en/news/285408743.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285408743.md)
---

# Mabwell Plans Up to RMB 1 Billion Targeted Debt Issue to Reshape Capital Structure

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest announcement is out from Mabwell (Shanghai) Bioscience Co., Ltd. Class H ( (HK:2493) ).

Mabwell (Shanghai) Bioscience Co., Ltd. plans to optimize its capital structure by registering and issuing targeted debt financing instruments of up to RMB 1 billion through the National Association of Financial Market Institutional Investors. The proposed bonds, with terms of up to three years, will be issued in the interbank bond market to institutional investors, aiming to broaden financing channels and lower funding costs.

Proceeds from the issuance will be used for repaying interest-bearing liabilities, funding project construction, and replenishing working capital, supporting the company’s ongoing strategic expansion. The board has approved the proposal and will seek shareholder approval at an upcoming extraordinary general meeting, while cautioning investors that the issuance remains subject to regulatory clearance and may not proceed.

**More about Mabwell (Shanghai) Bioscience Co., Ltd. Class H**

Mabwell (Shanghai) Bioscience Co., Ltd. is a China-based biopharmaceutical company listed in Hong Kong, operating in the life sciences sector with a focus on developing and commercializing innovative biologic therapies. The company taps domestic and international capital markets to support its research, manufacturing expansion, and broader strategic development in the healthcare industry.

**Average Trading Volume:** 6,906,072

**Current Market Cap:** HK$16.37B

For a thorough assessment of 2493 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [02493.HK](https://longbridge.com/en/quote/02493.HK.md)
- [688062.CN](https://longbridge.com/en/quote/688062.CN.md)

## Related News & Research

- [Mabwell Wins FDA Green Light for First-in-Human Trial of Novel Autoimmune Antibody 9MW5211](https://longbridge.com/en/news/285754749.md)
- [OCI Energy and CPS Energy break ground on Alamo City Battery Energy Storage Project | ING Stock News](https://longbridge.com/en/news/286964497.md)
- [Glytec and Advocate Health Win Top Innovation Award for Pediatric Insulin Safety](https://longbridge.com/en/news/286946637.md)
- [Why Indian PE funds are betting big on consumer brands and manufacturing](https://longbridge.com/en/news/286875914.md)
- [09:39 ETParkinson's Foundation Invests Nearly $600K in Innovative Care Grants](https://longbridge.com/en/news/286923742.md)